On May 16, 2017, at the 2017 Annual Meeting of Stockholders (the “Annual Meeting”) of Caladrius Biosciences, Inc. (the “Company”), the stockholders voted on and approved the seven proposals listed below. The following is a brief description of each matter voted upon at the Annual Meeting (for a full description of each such matter see the Company’s proxy statement), as well as the final voting results with respect to each such matter:

Proposal 1. The stockholders approved the adoption of the interest purchase agreement (the “Purchase Agreement”), dated as of March 16, 2017, by and among the Company., PCT, LLC, a Caladrius Company (“PCT”) and Hitachi Chemical Co. America, Ltd. (“Hitachi”), to which Hitachi will acquire from the Company the 80.1% interest in PCT that it does not own for $75.0 million in cash, subject to adjustment as described in the Proxy Statement. The final voting results with respect to this Proposal were as follows: 4,951,229 votes for; 155,736 votes against; 102,708 votes abstaining and 2,020,256 broker non-votes.

Proposal 2.>>The stockholders approved, on a non-binding advisory basis, the compensation that may be paid or become payable to the Company’s named executive officers in connection with the sale of PCT to Hitachi, including the agreements and understandings to which such compensation may be paid or become payable. The final voting results with respect to this Proposal were as follows: 3,956,483 votes for; 1,144,194 votes against; 108,996 votes abstaining and 2,020,256 broker non-votes.

Proposal 3.>>The stockholders approved an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the proposal to adopt the Purchase Agreement. The final voting results with respect to this Proposal were as follows: 5,032,360 votes for; 123,356 votes against; 53,957 votes abstaining and 2,020,256 broker non-votes.

Proposal 4.>>The stockholders elected one Class I director, Peter G. Traber, MD, to serve as a director on the Company’s Board of Directors until the annual meeting to be held in 2020. The final voting results with respect to this Proposal were as follows: 5,023,589 votes for; 124,898 votes against; 61,186 votes abstaining and 2,020,256 broker non-votes.

Proposal 5. The stockholders approved the adoption of the Company’s 2017 Employee Stock Purchase Plan. The final voting with respect to this Proposal were as follows: 4,698,972 votes for; 418,179 votes against; 92,522 votes abstaining and 2,020,256 broker non-votes.

Proposal 6. The stockholders approved, on a non-binding advisory basis, the executive compensation of the Company’s named executive officers as described in the Proxy Statement. The final voting results with respect to this Proposal were as follows: 3,956,871 votes for; 1,148,360 votes against; 104,442 votes abstaining and 2,020,256 broker non-votes.

Proposal 7.>>The stockholders ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017. The final voting results with respect to this Proposal were as follows: 7,087,013 votes for; 66,517 votes against and 76,399 votes abstaining.

About CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS)

Caladrius Biosciences, Inc., formerly NeoStem, Inc., through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development. The Company’s product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company’s T Regulatory Cell Technology is applicable to multiple autoimmune and allergic diseases.

CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) Recent Trading Information

CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) closed its last trading session down -0.35 at 5.02 with 69,014 shares trading hands.